<abstract xmlns="http://www.w3.org/1999/xhtml">

<italic>Objective:</italic> β2-agonist medications are thought to have adverse effects on bone density. Surgical denervation and intramuscular β2-agonist injections appear to have opposing effects on skeletal muscles. The present study has been designed to assess the effects of denervation of the masseter, intramuscular injection of a β2-agonist and the combination of both procedures, on bone density in the craniofacial skeleton in rats.
<italic>Materials and methods:</italic> Sprague-Dawley rats were prepared as four groups: 1. surgical sham + saline injection into the masseter (<italic>sham</italic>); 2. surgical denervation of the masseter (<italic>den</italic>.); 3. surgical denervation of the masseter + intramuscular formoterol injection into the affected muscle (<italic>den.+form</italic>.); 4. intramuscular formoterol injection into the masseter (<italic>form</italic>.). All specimens were submitted for CT examination and volumetric calculations of the mineralised bone tissue were performed.
<italic>Results:</italic> The sham and form. groups had a greater volume of mineralised bone in the zygoma on the experimental side compared with the control side. The maxilla on the experimental side had a higher volume of mineralised bone in the <italic>den.+form</italic>. and <italic>form</italic>. groups compared with the <italic>sham</italic> and <italic>den</italic>. groups. The control side of the maxilla had a higher volume of mineralised bone in the <italic>den</italic>.+<italic>form</italic>. and <italic>form</italic>. groups compared with the <italic>den</italic>. group only.
<italic>Conclusion:</italic> Intramuscular administration of formoterol appears to induce a bilateral increase in bone mineral density in the maxilla and the zygoma, likely explained as a secondary effect of the well-described increase in muscle mass and strength associated with β2-agonist administration.
</abstract>

Objective: β2-agonist medications are thought to have adverse effects on bone density. Surgical denervation and intramuscular β2-agonist injections appear to have opposing effects on skeletal muscles. The present study has been designed to assess the effects of denervation of the masseter, intramuscular injection of a β2-agonist and the combination of both procedures, on bone density in the craniofacial skeleton in rats.
Materials and methods: Sprague-Dawley rats were prepared as four groups: 1. surgical sham + saline injection into the masseter (sham); 2. surgical denervation of the masseter (den.); 3. surgical denervation of the masseter + intramuscular formoterol injection into the affected muscle (den.+form.); 4. intramuscular formoterol injection into the masseter (form.). All specimens were submitted for CT examination and volumetric calculations of the mineralised bone tissue were performed.
Results: The sham and form. groups had a greater volume of mineralised bone in the zygoma on the experimental side compared with the control side. The maxilla on the experimental side had a higher volume of mineralised bone in the den.+form. and form. groups compared with the sham and den. groups. The control side of the maxilla had a higher volume of mineralised bone in the den.+form. and form. groups compared with the den. group only.
Conclusion: Intramuscular administration of formoterol appears to induce a bilateral increase in bone mineral density in the maxilla and the zygoma, likely explained as a secondary effect of the well-described increase in muscle mass and strength associated with β2-agonist administration.

Denervation and β2-adrenoceptor-agonist administration on craniofacial bone density

Paediatric Dentistry, University of Melbourne

Australasian Orthodontic Journal

This work is licensed under the Creative Commons Attribution 4.0 International License.

Denervation and β-adrenoceptor-agonist administration on craniofacial bone density

Objective: β2-agonist medications are thought to have adverse effects on bone density. Surgical denervation and intramuscular β2-agonist injections appear to...

Denervation and β₂-adrenoceptor-agonist administration on craniofacial bone density

Online veröffentlicht: 01. Aug. 2023

Seitenbereich: 32 - 38

Eingereicht: 01. Juni 2012

Akzeptiert: 01. Dez. 2013

DOI: https://doi.org/10.2478/aoj-2014-0004

© 2014 Brendan Fitzpatrick et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.